文献速递肿瘤 PET/CT核素与放射性配体治疗

PET早期代谢反应预测EGFR突变肺癌未知获得性耐药机制患者对下一线靶向治疗的敏感性

Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance.
PubMed 文献 · J Nucl Med · 2024-06-03

这项II期研究纳入14例EGFR突变肺癌且对第一/二代EGFR TKI耐药、EGFR p.T790M检测阴性的患者,短程奥希替尼后以18F-FDG PET评估代谢反应。5例(36%)达到代谢反应并继续奥希替尼,中位治疗持续时间未达到(95%CI,24个月至不可估计),中位无进展生存期18.7个月(95%CI,14.6个月至不可估计),中位总生存期41.5个月。作者认为该策略可早期识别未知耐药机制患者并从序贯奥希替尼中获得显著临床获益。

要点

  • 14例EGFR突变肺癌、T790M阴性且对第一/二代EGFR TKI耐药患者入组II期研究。
  • 5例(36%)短程奥希替尼后18F-FDG PET达到代谢反应并继续奥希替尼。
  • 代谢反应者中位无进展生存期18.7个月,中位总生存期41.5个月。

核心结论

  • 将诊疗一体化奥希替尼治疗与PET早期代谢反应评估相连接,可早期识别未知TKI耐药机制并从序贯奥希替尼中获得显著临床获益的患者。
  • 作者认为这为依赖可靶向驱动癌基因的肺癌患者定义了靶向治疗个体化的新范式。

研究设计与样本

  • II期研究,纳入14例EGFR突变肺癌且对第一或第二代EGFR TKI耐药、EGFR p.T790M检测阴性的患者。

主要发现

  • 5例患者(36%)达到代谢18F-FDG PET反应并继续奥希替尼。
  • 代谢反应者中位治疗持续时间未达到(95%CI,24个月至不可估计)。
  • 代谢反应者中位无进展生存期为18.7个月(95%CI,14.6个月至不可估计)。
  • 代谢反应者中位总生存期为41.5个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeted therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has established the precision oncology paradigm in lung cancer. Most patients with EGFR-mutated lung cancer respond but eventually acquire resistance. Methods: Patients exhibiting the EGFR p.T790M resistance biomarker benefit from sequenced targeted therapy with osimertinib. We hypothesized that metabolic response as detected by 18F-FDG PET after short-course osimertinib identifies additional patients susceptible to sequenced therapy. Results: Fourteen patients with EGFR-mutated lung cancer and resistance to first- or second-generation EGFR TKI testing negatively for EGFR p.T790M were enrolled in a phase II study. Five patients (36%) achieved a metabolic 18F-FDG PET response and continued osimertinib. In those, the median duration of treatment was not reached (95% CI, 24 mo to not estimable), median progression-free survival was 18.7 mo (95% CI, 14.6 mo to not estimable), and median overall survival was 41.5 mo. Conclusion: Connecting theranostic osimertinib treatment with early metabolic response assessment by PET enables early identification of patients with unknown mechanisms of TKI resistance who derive dramatic clinical benefit from sequenced osimertinib. This defines a novel paradigm for personalization of targeted therapies in patients with lung cancer dependent on a tractable driver oncogene.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Schuler M, Hense J, Darwiche K, et al. Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance. J Nucl Med. 2024. PMID: 38575188. doi:10.2967/jnumed.123.266979

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。